Ascendis Pharma A/S (ASND) vs Jazz Pharmaceuticals (JAZZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Jazz Pharmaceuticals (JAZZ) has outperformed Ascendis Pharma A/S (ASND) over the past year, gaining 68.4% versus a gain of 8.8%. Over five years, JAZZ leads with a +64.3% price change compared with +42.8% for ASND. Ascendis Pharma A/S is the larger company by market cap ($15.03 billion vs $15.01 billion), about 1.0 times the size.
On valuation, Jazz Pharmaceuticals trades at a lower forward P/E (8.9x vs 21.1x for Ascendis Pharma A/S).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASND | JAZZ |
|---|---|---|
| Share price | $228.41 | $231.19 |
| Market cap | $15.03B | $15.01B |
| 1-day change | +1.04% | -0.09% |
| YTD return | +7.11% | +35.99% |
| 1-year return | +8.84% | +68.36% |
| 5-year return | +42.77% | +64.31% |
| P/E ratio (TTM) | 17.50 | 15.85 |
| Forward P/E | 21.11 | 8.93 |
| EPS (TTM) | $13.05 | $14.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $4.27B |
| Revenue growth (YoY) | — | +4.88% |
| Net income (latest FY) | — | $-356.15M |
| Operating margin | — | -10.08% |
| Net margin | — | -8.35% |
| 52-week high | $282.15 | $266.38 |
| 52-week low | $186.05 | $128.80 |
| Distance from 52-week high | -19.05% | -13.21% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +33.90% | +27.38% |
| Average volume | 656.21K | 854.86K |
| Shares outstanding | 65.80M | 64.91M |
| Employees | 1,189 | 2,890 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JAZZ has outperformed ASND by 59.5 percentage points over the past year.
About Ascendis Pharma A/S
ASND stock →Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,189 employees
About Jazz Pharmaceuticals
JAZZ stock →Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,890 employees
ASND vs JAZZ FAQ
Which is bigger, Ascendis Pharma A/S or Jazz Pharmaceuticals?
Ascendis Pharma A/S (ASND) is larger, with a market capitalization of $15.03B compared with $15.01B for Jazz Pharmaceuticals (JAZZ).
Which stock has performed better over the past year, ASND or JAZZ?
JAZZ returned +68.36% over the past 12 months, compared with +8.84% for ASND (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ASND or JAZZ?
JAZZ has the lower trailing P/E at 15.8, versus 17.5 for ASND. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Ascendis Pharma A/S and Jazz Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.